The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for PDS Biotechnology Corporation (PDSB) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $7.02. The PDS Biotechnology Corporation has recorded 16,778 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
PDS Biotechnology Corporation is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $7.02 and fluctuated between $7.64 as its day high and $6.61 as its day low. The current market capitalization of PDS Biotechnology Corporation is $208.00M. A total of 1.01 million shares were traded on the day, compared to an average of 619.52K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, PDSB has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 1 BUYs and 1 SELLs from insiders. Insiders purchased 219,535 shares during that period but sold 175,184.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for PDSB in the last 3 months, the mean price target is $19.43 with high estimates of $25.00 and low estimates of $12.00. In terms of 52-week highs and lows, PDSB has a high of $13.65 and a low of $2.89.
As of this writing, PDSB has an earnings estimate of -$0.28 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.26 per share and a lower estimate of -$0.33. The company reported an EPS of -$0.2 in the last quarter, which was 28.60% higher than expectations of -$0.28.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 7 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PDSB is Overweight with a score of 5.00. A total of 7 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.